MYC Degradation
Open accessThe DOI matches its Crossref record; 111 of the 114 references it cites were found in a registry or an index.
Abstract
The MYC oncoprotein is an essential transcription factor that regulates the expression of many genes involved in cell growth, proliferation, and metabolic pathways. Thus, it is important to keep MYC activity in check in normal cells in order to avoid unwanted oncogenic changes. Normal cells have adapted several ways to control MYC levels, and these mechanisms can be disrupted in cancer cells. One of the major ways in which MYC levels are controlled in cells is through targeted degradation by the ubiquitin-proteasome system (UPS). Here, we discuss the role of the UPS in the regulation of MYC protein levels and review some of the many proteins that have been shown to regulate MYC protein stability. In addition, we discuss how this relates to MYC transcriptional activity, human cancers, and therapeutic targeting.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We show that DT-061 binds a unique heterotrimeric regulatory pocket to selectively stabilize the B56α-PP2A holoenzyme thereby inducing cell death and attenuating tumor growth through B56α directed substrate dephosphorylation, including its most well characterized substrate, the oncogenic protein c-MYC (Allen-Petersen et al., 2018; Arnold and Sears, 2006; Farrell and Sears, 2014; Sheppard et al., 2”
From Selective PP2A enhancement through biased heterotrimer stabilization (2020) · cites this paper as Farrell and Sears, 2014
Citations
Cites
Function and regulation of cullin–RING ubiquitin ligases
Petroski, M. D., & Deshaies, R. J. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1547 · Cited by 2,148
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
A genomic and functional inventory of deubiquitinating enzymes.
Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., & Bernards, R. (2005) · Cell · doi:10.1016/j.cell.2005.11.007 · Cited by 1,854
c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715
Max: A Helix-Loop-Helix Zipper Protein That Forms a Sequence-Specific DNA-Binding Complex with Myc
Blackwood, E. M., & Eisenman, R. N. (1991) · Science · doi:10.1126/science.2006410 · Cited by 1,697
Transcriptional Amplification in Tumor Cells with Elevated c-Myc
Lin, C. Y., Lovén, J., Rahl, P. B., Paranal, R. M., Burge, C. B., Bradner, J. E., Lee, T. I., & Young, R. A. (2012) · Cell · doi:10.1016/j.cell.2012.08.026 · Cited by 1,513
Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability
Sears, R., Nuckolls, F., Haura, E., Taya, Y., Tamai, K., & Nevins, J. R. (2000) · Genes & Development · doi:10.1101/gad.836800 · Cited by 1,393
Self-citationc-Myc Regulates Transcriptional Pause Release
Rahl, P. B., Lin, C. Y., Seila, A. C., Flynn, R. A., McCuine, S., Burge, C. B., Sharp, P. A., & Young, R. A. (2010) · Cell · doi:10.1016/j.cell.2010.03.030 · Cited by 1,279
SCF and Cullin/RING H2-Based Ubiquitin Ligases
Deshaies, R. J. (1999) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.15.1.435 · Cited by 1,242
MYC oncogenes and human neoplastic disease
Nesbit, C. E., Tersak, J. M., & Prochownik, E. V. (1999) · Oncogene · doi:10.1038/sj.onc.1202746 · Cited by 1,158
Cited by
Items 101–200 of 471
RING-finger E3 ligases regulatory network in PI3K/AKT-mediated glucose metabolism
Wang, W., Shi, B., Cong, R., Hao, M., Peng, Y., Yang, H., Song, J., Feng, D., Zhang, N., & Li, D. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01162-7 · Cited by 53
“The MYC oncoprotein is an important transcription factor that regulates many genes involved in cell growth, proliferation, and metabolic pathways [44].”
BackgroundAcidity suppresses CD8 + T-cell function by perturbing IL-2, mTORC1, and c-Myc signaling
de Silly, R. V., Pericou, L., Seijo, B., Crespo, I., Coukos, G., & Irving, M. B. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00235-w · Cited by 54
“Accordingly, although we did not observe changes in phosphorylation of T58 or S62 (the residues mostly commonly involved in driving proteasomal degradation or stabilization of c-Myc, respectively, (Farrell and Sears, 2014), we observed higher c-Myc accumulation upon proteasome inhibition.”
Tilting MYC toward cancer cell death
Harrington, C. T., Sotillo, E., Dang, C. V., & Thomas‐Tikhonenko, A. (2021) · Trends in cancer · doi:10.1016/j.trecan.2021.08.002 · Cited by 53
The PHLPP2 phosphatase is a druggable driver of prostate cancer progression
Nowak, D. G., Cohen‐Katsenelson, K., Watrud, K. E., Chen, M., Mathew, G., D’Andrea, V. D., Lee, M. F., Swamynathan, M. M., Casanova‐Salas, I., Jibilian, M. C., et al. (2019) · The Journal of Cell Biology · doi:10.1083/jcb.201902048 · Cited by 51
“These results confirmed the previously proposed dominant role of T58 phosphorylation in dictatingMyc levels (Sears, 2004; Farrell and Sears, 2014) and introduced Phlpp2 as a key regulator.”
ResultKim, C., Lee, H. J., Jung, J. H., Kim, Y. H., Jung, D., Sohn, E. J., Lee, J. H., Woo, H. J., Baek, N., Kim, Y. C., et al. (2015) · Phytotherapy Research · doi:10.1002/ptr.5342 · Cited by 47
Deubiquitinating c-Myc: USP36 steps up in the nucleolus
Sun, X., Sears, R. C., & Dai, M. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1093713 · Cited by 48
“The MBI contains 2 critical residues, Threonine 58 (T58) and Serine 62 (S62), whose dynamic phosphorylation controls Myc protein stability in response to cell growth signals.(5,6,9,10) The MBII is critical for recruiting key Myc transactivation co-activators such as TRAAP, GCN5, TIP48, TIP49, TIP60, CBP/p300, BAF53 as…”
BackgroundSelf-citationFunctional and biological heterogeneity of KRAS Q61 mutations
Huynh, M. V., Hobbs, G. A., Schaefer, A., Pierobon, M., Carey, L. M., Diehl, J. N., DeLiberty, J. M., Thurman, R. D., Cooke, A. R., Goodwin, C. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2694 · Cited by 46
Xi, Z., Mu, Y., Li, Y., Xie, C., Holst, J., Liu, T., Cai, S., Lao, Y., Tan, H., Xu, H., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.123 · Cited by 46
“It is worth noting that, although several proteins can stimulate c-MYC protein degradation, some can also stimulate c-MYC transcriptional activity.(34) FBXW7 is one of the few that stimulate c-MYC degradation by ubiquitination(35) and also inhibits c-MYC transcriptional activity.”
BackgroundPathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Schick, M., Habringer, S., Nilsson, J. A., & Keller, U. B. (2017) · British Journal of Haematology · doi:10.1111/bjh.14917 · Cited by 47
“MYC stability and its proteasomal degradation is tightly regulated and frequently impaired in haematological malignancies (reviewed in (Farrell & Sears, 2014).”
BackgroundUbiquitination regulation of aerobic glycolysis in cancer
Xie, Y., Wang, M., Xia, M. H., Guo, Y., Zu, X., & Zhong, J. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120322 · Cited by 54
Multiple Roles of MYC in Integrating Regulatory Networks of Pluripotent Stem Cells
Fagnocchi, L., & Zippo, A. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00007 · Cited by 45
Human UTP14a promotes colorectal cancer progression by forming a positive regulation loop with c-Myc
Zhang, J., Ren, P., Xu, D., Liu, X., Liu, Z., Zhang, C., Li, Y., Wang, L., Du, X., & Xing, B. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.010 · Cited by 48
Acidic fibroblast growth factor underlies microenvironmental regulation of MYC in pancreatic cancer
Bhattacharyya, S., Oon, C. H., Kothari, A., Horton, W. R., Link, J. M., Sears, R. C., & Sherman, M. H. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20191805 · Cited by 49
“MYC protein is very short-lived, and its expression and activity are exclusively dependent on mitogenic signals (Farrell and Sears, 2014; Soucek and Evan, 2010).”
BackgroundSelf-citationYan, Y., Zhou, B. O., Chen, Q., Vasquez, A., Kamra, M., Chatterjee, A., Lee, Y., Yuan, X., Ellis, L., Vizio, D. D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28340-6 · Cited by 48
Tao, L., Li, D., Mu, S., Guanjing, T., & Yan, G. (2022) · Laboratory Investigation · doi:10.1038/s41374-022-00731-9 · Cited by 46
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products
Chan, K. I., Zhang, S., Li, G., Xu, Y., Cui, L., Wang, Y., Su, H., Tan, W., & Zhong, Z. (2024) · Aging and Disease · doi:10.14336/ad.2023.0520 · Cited by 49
ELL targets c-Myc for proteasomal degradation and suppresses tumour growth
Chen, Y., Zhou, C., Ji, W., Mei, Z., Hu, B., Zhang, W., Zhang, D., Wang, J., Liu, X., Ouyang, G., et al. (2016) · Nature Communications · doi:10.1038/ncomms11057 · Cited by 47
“The expression of transfected HA-c-Myc, HA-ELL and HA-ELL(C595A) was confirmed (Fig.”
InfluentialMYC-nick promotes cell migration by inducing fascin expression and Cdc42 activation
Anderson, S., Poudel, K. R., Roh‐Johnson, M., Brabletz, T., Yu, M., Borenstein‐Auerbach, N., Grady, W., Bai, J., Moens, C. B., Eisenman, R. N., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610994113 · Cited by 43
“MYC is a very short-lived protein, and multiple E3 ligases have been implicated in regulating MYC protein turnover through the ubiquitin–proteasome system (12).”
BackgroundAi, G., Dachineni, R., Muley, P., Tummala, H., & Bhat, G. J. (2015) · Tumor Biology · doi:10.1007/s13277-015-3959-0 · Cited by 57
Wu, Z., Han, X., Tan, G., Zhu, Q., Chen, H., Xia, Y., Gong, J., Wang, Z., Wang, Y., & Yan, J. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s224062 · Cited by 45
“FBW-7 is a well-known E3 ligase responsible for c-myc ubiquitination.(34) In FBW-7 deficient cells, dioscinmediated c-myc ubiquitination was almost completely diminished, verifying that FBW-7 was involved in the regulation of c-myc by dioscin.”
BackgroundKlomp, J. E., Lee, Y. S., Goodwin, C. M., Papke, B., Klomp, J. A., Waters, A. M., Stalnecker, C. A., DeLiberty, J. M., Drizyte‐Miller, K., Yang, R. Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110060 · Cited by 49
“ERK blocks MYC degradation by direct phosphorylation of MYC at S62 (Farrell and Sears, 2014; Vaseva et al., 2018), and conversely ERKi promotes loss of MYC by enhancing its degradation.”
DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC
Wang, Y., Ju, L., Wang, G., Qian, K., Jin, W., Li, M., Yu, J., Shi, Y., Wang, Y., Zhang, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38160-x · Cited by 43
Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc
D’Artista, L., Bisso, A., Piontini, A., Doni, M., Verrecchia, A., Kress, T. R., Morelli, M. J., Sal, G. D., Amati, B. B., & Campaner, S. (2016) · Oncotarget · doi:10.18632/oncotarget.7846 · Cited by 41
“Second no data were available concerning the identity of the Ub-ligase responsible for Myc degradation following Ser 62 de-phosphorylation [7]: based on independent work [20, 21], this is commonly surmised to be the T58P-dependent ligase Fbw7 [39, 47].”
Strategies to target the cancer driver MYC in tumor cells
Weber, L. I., & Hartl, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1142111 · Cited by 52
“Ubiquitinated MYC is then degraded in the 26S– proteasomal complex (2, 36, 136).”
BackgroundGlucose Metabolism Reprogrammed by Overexpression of IKKϵ Promotes Pancreatic Tumor Growth
Zubair, H., Azim, S., Srivastava, S. K., Ahmad, A., Bhardwaj, A., Khan, M. A., Patel, G. K., Arora, S., Carter, J. E., Singh, S., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1666 · Cited by 40
Therapeutic targets of cancer drugs: Modulation by melatonin
Moloudizargari, M., Moradkhani, F., Hekmatirad, S., Fallah, M., Asghari, M. H., & Reiter, R. J. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118934 · Cited by 45
Differential Cytotoxicity Mechanisms of Copper Complexed with Disulfiram in Oral Cancer Cells
Chen, S.-Y., Chang, Y., Liu, S., Chen, G., Lee, S., & Huang, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073711 · Cited by 41
“We and others previously reported that cellular stress enhances c-Myc degradation [32,33].”
BackgroundHu, Y., Su, Y., He, Y., Liu, W., & Xiao, B. (2021) · Gene · doi:10.1016/j.gene.2021.145718 · Cited by 40
MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer
Stefan, E., & Bister, K. (2017) · Current topics in microbiology and immunology · doi:10.1007/82_2017_4 · Cited by 44
The impact of phosphatases on proliferative and survival signaling in cancer
Narla, G., Sangodkar, J., & Ryder, C. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2826-8 · Cited by 47
“At the post-translational level, c-Myc undergoes a series of coordinated phosphorylation/dephosphorylation events, with intervening proline isomerization (reviewed in [96]; see Fig.”
Ohara, Y., Tang, W., Liu, H., Yang, S., Dorsey, T. H., Cawley, H., Moreno, P., Chari, R., Guest, M., Azizian, A., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113434 · Cited by 45
“32 Given that SERPINB3 functions as a serine/cysteine protease inhibitor, 18 and calpain is a cysteine protease, 33 we explored whether SERPINB3 inhibits calpain, thereby curbing MYC protein degradation (Figure 4F).”
Liu, W., Ding, Z., Tao, Y., Liu, S., Jiang, M., Yi, F., Wang, Z., Han, Y., Zong, H., Li, D., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02051-6 · Cited by 43
“As a labile protein with a short half-life, c-Myc is primarily degraded through the ubiquitin-proteasome pathway [18].”
BackgroundSCP1 regulates c-Myc stability and functions through dephosphorylating c-Myc Ser62
Wang, W., Liao, P., Shen, M., Chen, T., Chen, Y., Li, Y. C. A. B. W. H., Lin, X., Ge, X., & Wang, P. (2015) · Oncogene · doi:10.1038/onc.2015.106 · Cited by 38
Common Mechanisms of Onset of Cancer and Neurodegenerative Diseases
Ariga, H. (2015) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b15-00125 · Cited by 40
Liu, Y., Liao, Y., Xiang, L., Jiang, K., Li, S., Huangfu, M., & Sun, S. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-1047-0 · Cited by 36
“Overexpression and mutations of the c-myc gene may lead to abnormalities in the regulation of multiple genes and eventually cause the formation of carcinomas [23].”
BackgroundChen, J., Li, W., Cui, K., Ji, K., Xu, S., & Xu, Y. (2018) · Oncogene · doi:10.1038/s41388-018-0331-z · Cited by 37
TAZ functions as a tumor suppressor in multiple myeloma by downregulating MYC
Grieve, S., Wajnberg, G., Lees, M., Chacko, S. M., Weir, J. A., Crapoulet, N., & Reiman, T. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000374 · Cited by 41
“FBW7 is one of the best-characterized E3 ligases that targets MYC for degradation after phosphorylation of T58 by glycogen synthase kinase b.(57,58) The precise mechanisms mediating TAZdependent loss of MYC expression in MM remain important areas of study andmay lead to enhanced efficacy of therapies that target MYC.”
BackgroundThe Role of MYC and PP2A in the Initiation and Progression of Myeloid Leukemias
Pippa, R., & Odero, M. D. (2020) · Cells · doi:10.3390/cells9030544 · Cited by 41
“CIP2A, also named KIAA1524, is a scaffold protein that stabilizes MYC by inhibiting the PP2Aregulated de-phosphorylation on the residue S62 [93].”
BackgroundInfluentialZhang, Z., Gao, Q., & Wang, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16291 · Cited by 37
Smedt, E. D., Devin, J., Muylaert, C., Robert, N., Requirand, G., Vlummens, P., Vincent, L., Cartron, G., Maes, K., Moreaux, J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003217 · Cited by 35
Rosselot, C., Kumar, A., Lakshmipathi, J., Zhang, P., Lu, G., Katz, L. S., Prochownik, E. V., Stewart, A. F., Lambertini, L., Scott, D. K., et al. (2019) · Diabetes · doi:10.2337/db18-1368 · Cited by 37
“F: Immunoblots of extracts of INS-1 832/13 cells after treatment with the indicated adenovirus, glucose concentrations, or 5 nmol/L endothall (Endo) using antibodies against Myc, Myc pSer62, and GAPDH as a loading control.”
BackgroundInfluentialLiu, H., Gu, Y., Yin, J., Zheng, G., Wang, C., Zhang, Z., Deng, M., Liu, J., Jia, X., & He, Z. (2014) · Cellular Signalling · doi:10.1016/j.cellsig.2014.08.010 · Cited by 39
Beyond gene expression: how MYC relieves transcription stress
Papadopoulos, D., Uhl, L., Ha, S. A., & Eilers, M. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.06.008 · Cited by 35
Waters, A. M., Khatib, T. O., Papke, B., Goodwin, C. M., Hobbs, G. A., Diehl, J. N., Yang, R. Y., Edwards, A. C., Walsh, K. H., Sulahian, R., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109291 · Cited by 39
“ERK phosphorylates MYC at residue S62 (pMYCS62) and primes it for GSK3β-mediated phosphorylation at residue T58 (pMYCT58) (Farrell and Sears, 2014).”
BackgroundCooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation
Simmons, J. K., Michalowski, A. M., Gamache, B. J., Dubois, W., Patel, J. D., Zhang, K., Gary, J. M., Zhang, S., Gaikwad, S. M., Connors, D. E., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0171 · Cited by 33
“Increased phosphorylation of the threonine 58 residue, known to destabilize the MYC protein (36, 39), was observed after combination treatment in L363 cells, while phosphorylation levels of the stabilizing serine 62 residue were already absent just 10 minutes after treatment (Fig.”
Inhibition of acetylation, is it enough to fight cancer?
López-Bañuelos, L., & Vega, L. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103752 · Cited by 32
Deng, Z., & Richardson, D. R. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000795 · Cited by 34
“Since proteasomal degradation is involved in the regulation of Myc protein function in cancer cells (Welcker et al., 2004; Popov et al., 2007; Choi et al., 2010; Farrell and Sears, 2014; Tavana et al., 2016), ubiquitinationmay also participate inMyc protein regulation.”
BackgroundLi, J., Rodríguez, Y., Cheng, C., Zeng, L., Wong, E. Y. M., Xu, C. Y., Zhou, M., & Xu, P. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00499-16 · Cited by 36
“Phosphorylation of Myc at S62 and T58 is critical for controlling Myc turnover in diverse cellular processes, such as the cell cycle and tumorigenesis (10).”
BackgroundChen, J., Huang, X., Tao, C., Xiao, T., Li, X., Zeng, Q., Ma, M., & Wu, Z. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00391 · Cited by 35
DLGAP5 enhances bladder cancer chemoresistance by regulating glycolysis through MYC stabilization
Deng, Z., Zhou, F., Li, M., Jin, W., Yu, J., Wang, G., Qian, K., Ju, L., Zhang, Y., Xiao, Y. P., et al. (2025) · Theranostics · doi:10.7150/thno.102730 · Cited by 33
Xu, K., Ding, J., Zhou, L., Li, D., Luo, J., Wang, W., Shang, M., Lin, B., Zhou, L., & Zheng, S. (2022) · Cells · doi:10.3390/cells12010025 · Cited by 34
“The oncogenic transcription factor c-Myc is reported as a short-lived protein that is usually degraded by the ubiquitin–proteasome pathway [26].”
BackgroundGamabufotalin triggers c-Myc degradation via induction of WWP2 in multiple myeloma cells
Yu, Z., Li, T., Wang, C., Deng, S., Zhang, B., Huo, X., Zhang, B., Wang, X., Zhong, Y., & Ma, X. (2016) · Oncotarget · doi:10.18632/oncotarget.7398 · Cited by 30
Li, Y., Challagundla, K. B., Sun, X., Zhang, Q., & Dai, M. (2014) · Oncotarget · doi:10.18632/oncotarget.2728 · Cited by 31
Csizmók, V., Montecchio, M., Lin, H., Tyers, M., Sunnerhagen, M., & Forman-Kay, J. D. (2017) · Structure · doi:10.1016/j.str.2017.11.003 · Cited by 30
From the Evasion of Degradation to Ubiquitin-Dependent Protein Stabilization
Ahmad, Y. A., Oknin-Vaisman, A., Bitman-Lotan, E., & Orian, A. (2021) · Cells · doi:10.3390/cells10092374 · Cited by 26
Targeting Myc Interacting Proteins as a Winding Path in Cancer Therapy
Zhou, Y., Gao, X., Meng, Y. G., Yang, B., He, Q., & Cao, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.748852 · Cited by 33
Resveratrol Downregulates miR‐155‐5p to Block the Malignant Behavior of Gastric Cancer Cells
Su, N., Li, L., Zhou, E., Li, H., Wu, S., & Cao, Z. (2022) · BioMed Research International · doi:10.1155/2022/6968641 · Cited by 30
“Cyclin D1 plays a vital role in cancer pathogenesis as its upregulated expression drives unchecked cellular proliferation [32]. c-Myc acts as a transcription factor and plays a vital role in controlling cell growth, vitality, apoptosis, and cellular transformation [33, 34].”
The long noncoding RNA regulation at the MYC locus
Xiang, J., Yang, L. C., & Chen, L. (2015) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2015.07.001 · Cited by 29
“Also, the stability of MYC protein is highly controlled as well in cells through targeted degradation by the ubiquitin-proteasome system (reviewed in [3]).”
BackgroundA moving target: structure and disorder in pursuit of Myc inhibitors
Bayliss, R. W., Burgess, S. G., Leen, E. N., & Richards, M. W. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160328 · Cited by 34
Sim, D. Y., Lee, H., Ahn, C., Park, J.-E., Park, S., Kil, B. J., Shim, B., Kim, B., & Kim, S.-H. (2024) · International Journal of Biological Sciences · doi:10.7150/ijbs.93462 · Cited by 32
“Myc levels are regulated in normal cells via targeted degradation by the ubiquitin-proteasome system (UPS) including FBW7 or SKP2 [40].”
BackgroundZhao, L., Yu, N., Zhai, Y., Yang, Y., Wang, Y., Yang, Y., Gong, Z., Zhang, Y., Zhang, X., & Guo, W. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06890-5 · Cited by 34
Peng, Z., Pang, H., Wu, H., Peng, X., Tan, Q., Lin, S., & Wei, B. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11776 · Cited by 28
Schweitzer, C. J., Zhang, F., Boyer, A., Valdez, K., Cam, M., & Liang, T. J. (2017) · Journal of Virology · doi:10.1128/jvi.01166-17 · Cited by 29
“It is possible that HCV infection, in addition to increasing MYC transcription at a later time, causes an earlier functional alteration of MYC that is mediated through alternate mechanisms such as posttranscriptional modification or degradation (44) and suppresses NDRG1 expression.”
BackgroundZhang, S., Hu, Y., Wu, Z., Zhou, X., Wu, T., Li, P., Lian, Q., Xu, S., Gu, J., Chen, L., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.11.022 · Cited by 31
Regulation and role of the PP2A-B56 holoenzyme family in cancer
Peris, I., Romero-Murillo, S., Vicente, C., Narla, G., & Odero, M. D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188953 · Cited by 30
Doha, Z. O., & Sears, R. C. (2023) · Pathophysiology · doi:10.3390/pathophysiology30030031 · Cited by 28
“In addition to transcriptional and mRNA regulation, MYC protein stability and activity are regulated by several post-translational modifications as well as multiple ubiquitin ligases [31–33].”
BackgroundSelf-citationNayak, R. C., Hegde, S., Althoff, M. J., Wellendorf, A. M., Mohmoud, F., Perentesis, J. P., Reina‐Campos, M., Reynaud, D., Zheng, Y., Díaz-Meco, M. T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07846-y · Cited by 30
Hartl, M., Puglisi, K., Nist, A., Raffeiner, P., & Bister, K. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12636 · Cited by 30
“To test whether the observed MYC and CaM degradation depend on the ubiquitin/proteasome pathway (Farrell and Sears, 2014), more detailed kinetics were performed in the presence of the proteasome inhibitor MG-132 (Fig.”
BackgroundProtein Kinase D3 promotes the cell proliferation by activating the ERK1/c‐MYC axis in breast cancer
Liu, Y., Song, H., Yu, S., Huang, K., Ma, X., Zhou, Y., Yu, S., Zhang, J., & Chen, L. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.14772 · Cited by 30
Signatures of co-deregulated genes and their transcriptional regulators in colorectal cancer
Mastrogamvraki, N., & Zaravinos, A. (2020) · npj Systems Biology and Applications · doi:10.1038/s41540-020-00144-8 · Cited by 28
Martín, O. J., Schlösser, A., Furtwängler, R., Wegert, J., & Gessler, M. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02259-2 · Cited by 27
“EP400 or TRRAP [19], FBXW7, involved in N-MYC proteasomal degradation [20], and the ubiquitin-specific protease USP11, required for recruitment of BRCA1 and enhancement of transcriptional activation [21].”
BackgroundUpregulation of LYAR induces neuroblastoma cell proliferation and survival
Sun, Y., Atmadibrata, B., Yu, D. M. T., Wong, M., Liu, B., Ho, N., Ling, D., Tee, A. E., Wang, J. Y., Mungrue, I. N., et al. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.98 · Cited by 26
“responsive element E-Boxes at target gene promoters, leading to transcriptional activation.(8,24,25) In this study, we”
BackgroundMYC in T-cell acute lymphoblastic leukemia: functional implications and targeted strategies
Li, Q., Pan, S., Xie, T., & Liu, H. (2021) · Blood Science · doi:10.1097/bs9.0000000000000073 · Cited by 27
Stengel, S., Petrie, K. R., Sbirkov, Y., Stanko, C., Zadegan, F. G., Gil, V., Skopek, R., Kamiński, P., Szymański, Ł., Brioli, A., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18187 · Cited by 28
Harrington, C. T., Sotillo, E., Robert, A., Hayer, K. E., Bogusz, A. M., Psathas, J. N., Yu, D., Taylor, D. M., Dang, C. V., Klein, P. S., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0454-4 · Cited by 28
Wu, G., Su, J., Zeng, L., Deng, S., Huang, X., Ye, Y., Li, R., Bai, R., Zhuang, L., Li, M., et al. (2023) · Cell Death and Differentiation · doi:10.1038/s41418-023-01225-x · Cited by 30
“…subunit of the SCF E3 ubiquitin ligase that has been shown to interact with c-Myc in nucleus and stimulate c-Myc degradation via mediating c-Myc phosphorylation-independent ubiquitination [59 – 61], we next examined whether BCAN-AS1 regulates SKP2-mediated c-Myc ubiquitination.”
BackgroundQuintanal-Villalonga, À., Kawasaki, K., Redín, E., Uddin, F. Z., Rakhade, S., Durani, V., Sabet, A. H., Shafer, M., Karthaus, W. R., Zaidi, S., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01908-y · Cited by 30
Insights into the Role of microRNAs in Colorectal Cancer (CRC) Metabolism
Hon, K. W., Abidin, S. A. Z., Othman, I., & Naidu, R. (2020) · Cancers · doi:10.3390/cancers12092462 · Cited by 33
“In cancers, c-Myc is an essential transcription factor that is frequently expressed to activate the expression of many genes involved in cell proliferation and metabolism [73].”
BackgroundZacksenhaus, E., Liu, J.-K., Jiang, Z., Yao, Y., Xia, L., Shrestha, M., & Ben‐David, Y. (2016) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2016.10.003 · Cited by 30
Liao, W., Yang, W., Zhang, Y., FanHong, Z., 徐杰诚, Yan, Z., Mingxin, P., Xu, X., Zhou, S., Zeng, M., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658197 · Cited by 27
“The c-Myc oncoprotein is an essential transcription factor that regulates the expression of many genes involved in cell growth, proliferation, and metabolic pathways [40].”
BackgroundHongwiangchan, N., Sriratanasak, N., Wichadakul, D., Aksorn, N., Chamni, S., & Chanvorachote, P. (2021) · Pharmaceuticals · doi:10.3390/ph14111112 · Cited by 29
“Emerging research has shown that Akt affects the degradation of c-Myc via the ubiquitin proteasomal pathway [25].”
BackgroundGao, R., Wang, L., Cai, H., Zhu, J., & Yu, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0164086 · Cited by 25
Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma
Eberhardt, A., Hansen, J. N., Köster, J., Lotta, L. T., Wang, S., Livingstone, E., Qian, K., Valentijn, L. J., Zheng, Y. G., Schor, N. F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11556 · Cited by 24
“Phosphorylation at S62 (pS62) can stabilize MYC, whereas subsequent phosphorylation at T58 (pT58) promotes MYC proteolysis [16].”
BackgroundThe roles of FGFR3 and c-MYC in urothelial bladder cancer
Bogale, D. E. (2024) · Discover Oncology · doi:10.1007/s12672-024-01173-z · Cited by 27
“…ligases that directly ubiquitinate MYC like, TRUSS, β-TrCP, TRIM32 & Fbx29; deubiquitinating enzymes that cleave ubiquitin chains to antagonize the activity of ubiquitin ligases like Usp28 & Usp36; and those that indirectly regulate MYC stability like SIRT2 & NEMO (NF-kB essential modulator) [125].”
BackgroundInfluentialDeng, Q., Wu, M., & Deng, J. (2022) · Human Cell · doi:10.1007/s13577-022-00677-6 · Cited by 25
Cencioni, C., Scagnoli, F., Spallotta, F., Nasi, S., & Illi, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044217 · Cited by 34
“This event blocks T58 phosphorylation by GSK3β, leading to enhanced protein stability [180].”
BackgroundInositol pyrophosphates promote MYC polyubiquitination by FBW7 to regulate cell survival
Lolla, P., Shah, A., Unnikannan, C. P., Oddi, V., & Bhandari, R. (2021) · Biochemical Journal · doi:10.1042/bcj20210081 · Cited by 22
Chang, W.-H., Liu, Y., Hammes, E. A., Bryant, K. L., Cerione, R. A., & Antonyak, M. A. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102842 · Cited by 26
“However, phosphorylation of Thr 58 results in the dephosphorylation of Ser 62, targeting MYC for degradation (15).”
BackgroundInfluentialThe deubiquitinase USP38 promotes cell proliferation through stabilizing c-Myc
Xu, Z., Hu, H. Q., Fang, D., Wang, J., & Zhao, K. (2021) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2021.106023 · Cited by 21
Sehgal, P. D., Lanauze, C., Wang, X., Hayer, K. E., Torres-Diz, M., Leu, N. A., Sela, Y., Stanger, B. Z., Lengner, C. J., & Thomas-Tikhonenko, A. (2021) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-21-0666 · Cited by 22
“CHIR99021 inhibits the phosphorylation of MYC at Threonine-58 by GSK-3-b, which leads to phosphoMYC being targeted for ubiquitination and subsequent degradation (25).”
BackgroundLi, X., Tian, Z., Jin, H., Xu, J., Hua, X., Yan, H., Liufu, H., Wang, J., Li, J., Zhu, J., et al. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00273-18 · Cited by 22
“In contrast to previous studies showing that c-Myc could be posttranslationally regulated (55), as well as our published study showing that c-Myc protein degradation is regulated by FBW7 in arsenite-treated cells (56), Han and colleagues report that c-Myc activity is modulated by p63 via direct protein-protein interac…”
ResultJanghorban, M., Langer, E. M., Wang, X., Zachman, D., Daniel, C. J., Hooper, J., Fleming, W. H., Agarwal, A., & Sears, R. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188910 · Cited by 19
Self-citationTargeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc
Wang, Y., Ruan, D., Wang, Z., Yu, K., Rong, D., Liu, Z., Wang, F., Hu, J., Jin, Y., Wu, Q., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02515-3 · Cited by 20
“To date, the proteins involved in c-myc degradation have been systematically reviewed [35].”
BackgroundTargeting MYC: Multidimensional regulation and therapeutic strategies in oncology
Duan, Y., Liu, Z., Wang, Q., Zhang, J., Liu, J., Zhang, Z., & Li, C. (2024) · Genes & Diseases · doi:10.1016/j.gendis.2024.101435 · Cited by 38
“49,166 Several methods have been explored to improve the degradation of MYC, including the inhibition of PI3K to promote the action of GSK3 b and using small-molecule activators of PP2A (Fig.”
c-Myc-PD-L1 Axis Sustained Gemcitabine-Resistance in Pancreatic Cancer
Yao, J., Huang, M., Shen, Q., Ding, M. L., Yu, S., Guo, Y., Lin, Y., Zheng, Y., Chen, W., Yan, W., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.851512 · Cited by 22
Statins decrease the expression of c-Myc protein in cancer cell lines
Rao, P. S., & Rao, U. S. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03940-2 · Cited by 22
Šereš, M., Spacayova, K., Sulová, Z., Špaldová, J., Breier, A., & Pavlíková, L. (2025) · Cancers · doi:10.3390/cancers17020248 · Cited by 29
HECTD3 promotes gastric cancer progression by mediating the polyubiquitination of c-MYC
Zhang, G., Zhu, Q., Yan, X., Ci, M., Zhao, E., Hou, J., Wan, S., Lü, M., & Cui, H. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01001-9 · Cited by 21
“Existing reports indicate that c-MYC contains several domains and that act important roles, including the transaction activation domain (TAD), central portion domain (CP) and basic helix–loop–helix leucine zipper domain (bHLHZ) [17, 18].”
BackgroundWu, J., Luo, F., Xie, Y., Xiong, H., Gao, Y., Liu, G., & Zhang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943174 · Cited by 19
“Previous reports showed that the increased phosphorylation of Myc S62 promoted the stability of Myc protein, and phosphorylated S62 would also help Myc bind to GSK3b, which mediated phosphorylat ion of T58 and Myc ubiquitination degradation by FBW7 (32).”
BackgroundAsparagine bioavailability regulates the translation of MYC oncogene
Srivastava, S., Jiang, J., Misra, J., Seim, G. L., Staschke, K. A., Zhong, M., Zhou, L., Liu, Y., Chen, C., Davé, U. P., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02474-9 · Cited by 22
“In normal cells, c-MYC protein levels are tightly regulated; however, in cancer cells mutations in the upstream or downstream signaling cascade or the cis-regulatory elements of c-MYC can lead to aberrant high expression, which drives transformation and tumor progression [17, 18].”
Background
Metadata
- Authors
- Farrell, A. S., & Sears, R. C.
- Affiliations
- Oregon Health & Science University (US)
- ORCID
- Sears, R. C.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2014-03-01
- Volume
- 4
- Issue
- 3
- Pages
- a014365-a014365
- ISSN
- 2157-1422 (ISSN-L)
- PMC
- PMC3935390
- OpenAlex
- W4236967220
- Cited by
- 468
- References
- 114
- Citations by year
- 2026: 35 · 2025: 38 · 2024: 46 · 2023: 58 · 2022: 58 · 2021: 53 · 2020: 55 · 2019: 29 · 2018: 28 · 2017: 17 · 2016: 20 · 2015: 17 · 2014: 10
- Type
- posted content
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cold Spring Harbor Perspectives in Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- Myc oncoprotein, protein degradation, ubiquitin-proteasome system, MYC protein stability, transcriptional regulation, cancer, MYC-targeted therapy, cell proliferation
- MeSH terms
- Acetylation, Cell Communication, Humans, Neoplasms, Transcription, Genetic, Genes, myc, Ubiquitin, Proteasome Endopeptidase Complex, Protein Stability, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.